Targeting chondrocytes for arresting bony fusion in ankylosing spondylitis
Current treatments cannot significantly alleviate the radiographic progression in ankylosing spondylitis (AS), which results in joints stiffness and bony fusion of AS. Smo inhibitor sonidegib retards the pathological new bone formation in AS through targeting dysfunctional chondrogenesis.
Guardado en:
Autores principales: | Fenli Shao, Qianqian Liu, Yuyu Zhu, Zhidan Fan, Wenjun Chen, Shijia Liu, Xiaohui Li, Wenjie Guo, Gen-Sheng Feng, Haiguo Yu, Qiang Xu, Yang Sun |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/12886a3b76044df8b6656dcdbe796a6e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Management of ankylosing spondylitis with infliximab
por: Éric Toussirot, et al.
Publicado: (2009) -
Efficacy and safety of adalimumab in ankylosing spondylitis
por: Mounach A, et al.
Publicado: (2014) -
Advances in nanomedicine for the treatment of ankylosing spondylitis
por: Xi Y, et al.
Publicado: (2019) -
Serum IL-6 correlates with axial mobility index (Bath Ankylosing Spondylitis Metrology Index) in Brazilian patients with ankylosing spondylitis
por: Rabelo CF, et al.
Publicado: (2018) -
Sex differences in outcomes of total hip arthroplasty for the treatment of ankylosing spondylitis
por: Liang Zhang, et al.
Publicado: (2021)